Denavir Indication Understood By 99% of Respondents in Actual Use Study
This article was originally published in The Tan Sheet
Executive Summary
The proposed OTC use of SmithKline Beecham's Denavir for recurrent cold sores in immunocompetent adults was correctly understood by more than 99% of respondents in a large actual use study conducted by the company.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning